Zafarbakhsh Azam, Vaezi Atefeh, Haghjooy Javanmard Shaghayegh, Sabet Fahimeh, Dehghan Maryam
Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran.
Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2023 Jun 30;12:163. doi: 10.4103/abr.abr_142_22. eCollection 2023.
Coronavirus disease 2019 (COVID-19) is an infectious disease that the physiological changes in pregnancy can make pregnant patients more susceptible to more severe forms of this infection. Hence, the treatment of COVID-19 in pregnant women can be challenging. This study was designed to evaluate the safety and efficacy of Remdesivir in pregnant women with COVID-19.
This study was conducted on 150 pregnant women with moderate to severe COVID-19 infection. Remdesivir was prescribed and continued for 5 or 10 days according to the patient's condition. Maternal and pregnancy outcomes and also recovery rates were evaluated. Moreover, additional variables were examined: age, gestational age, symptoms, O2 saturation and laboratory tests at admission, the interval between symptom initiation and admission to hospital and Remdesivir prescription, hospitalization days, and ICU admission.
The mean age was 32.37 years. Cough and dyspnea were the most prevalent symptoms (74% and 68.7%, respectively). At the time of admission, 79 (52.7%) women needed low-flow oxygen support, 67 (44.7%) needed high-flow oxygen support, and 4 (2.7%) were intubated. Fifty-four (36%) patients required ICU care. In patients who died (12 women), Remdesivir was prescribed later than those discharged ( value, 0.04). Patients with favorable pregnancy outcomes received Remdesivir earlier than those with unfavorable pregnancy outcomes ( value: 0.008). The recovery rate was 70% (89.9% in the low-flow oxygen, 50.7% in the NIPPV/high flow oxygen, and 0% in the intubated women).
The results suggest that the early prescription of Remdesivir in pregnant women with moderate COVID-19 can improve the outcomes.
2019冠状病毒病（COVID-19）是一种传染病，妊娠期间的生理变化会使孕妇更容易感染这种疾病的更严重形式。因此，COVID-19孕妇的治疗具有挑战性。本研究旨在评估瑞德西韦对COVID-19孕妇的安全性和有效性。
本研究对150例中重度COVID-19感染的孕妇进行。根据患者病情，给予瑞德西韦并持续使用5或10天。评估孕产妇和妊娠结局以及恢复率。此外，还检查了其他变量：年龄、孕周、症状、入院时的氧饱和度和实验室检查、症状出现至入院及瑞德西韦处方的间隔时间、住院天数和入住重症监护病房情况。
平均年龄为32.37岁。咳嗽和呼吸困难是最常见的症状（分别为74%和68.7%）。入院时，79名（52.7%）女性需要低流量吸氧支持，67名（44.7%）需要高流量吸氧支持，4名（2.7%）需要插管。54名（36%）患者需要重症监护。在死亡患者（12名女性）中，瑞德西韦的处方时间晚于出院患者（P值，0.04）。妊娠结局良好的患者比妊娠结局不良的患者更早接受瑞德西韦治疗（P值：0.008）。恢复率为70%（低流量吸氧患者中为89.9%，无创通气/高流量吸氧患者中为50.7%，插管女性中为0%）。
结果表明，在中度COVID-19孕妇中早期使用瑞德西韦可改善结局。
